Strategy advisory specialized on innovative companies in Biotechnology, Med-Tech and Pharma

Investment advisory for generalist Private Equity and Venture Capital Funds or Family Offices with an interest in these industries

Dr. Alexandra Goll
"Know your options, take the smartest possible decision - and be successful."
Dr. Alexandra Goll, Managing Director Learn More


  • Innovation in healthcare is driven globally by drug development for new therapies, use of Big Data applications and progress in medical technologies. For best of success, good science needs to be paired with industry expertise and a robust international network to mitigate clinical, regulatory risk, and accelerate commercialization.
  • A successful market entry and reduced time-to-market are closely connected to getting the right partners on board at the right time.
  • Optimized processes, long-term financial planning, company building, and a deep understanding of industry dynamics, players, and developments allows to align the interests of management teams and investors.

Strategy Advice

  • Business Plan – Company Building and Product Strategy
  • Clinical Development, Commercialization, Market Entry
  • Partnering, Licensing
  • Financial Planning, Fundraising, Transaction Management
  • Turnaround
  • Interimsmanagement

Investment Advice

  • Deal Sourcing
  • Due Diligence / Valuation
  • Shareholder structure
  • Transaction Advice and Management
  • Shareholder Representation on Supervisory Boards


Alexandra Goll, PhD, nat. Sc., Managing Director

Dr. Alexandra Goll holds vast managerial and operational experience in the international pharmaceutical and biotechnology industry. She took responsibility as a general partner at TVM Capital Life Science in 1998, a specialized life science and biotechnology venture capital fund, overseeing and managing the strategic investment decisions, the investment process, deal structuring and exits until the year 2018. She is a jury member at the Deutscher Zukunftspreis and was jury member at the Fraunhofer Preis (2016-2019).

She took entrepreneurial responsibility serving in selected boards of private and public portfolio companies in Europe and the USA. She resumed responsibility of strategic development, advising with deep industry insight and leveraging her robust international network. She advised and led company building, financings, IPOs, partnering and licensing programs.

She initiated various lead investments proving a sense for outstanding business opportunities by investing in Actelion Ltd., Idenix Pharmaceuticals, Inc., partially sold to Novartis, and Pharmasset Inc. sold to Gilead Sciences, EUSA Pharma Ltd., sold to Jazz Pharmaceuticals Inc., amongst others.

She started her professional career as Global Business Leader for HIV and CMV, responsible for strategic marketing and business development for Virology at Roche. in Basel. She was involved in the clinical development and managing of commercialization strategies of Neupogen® (under an agreement with Amgen), Hivid®, Cymevene® and Valcyte®.

Alexandra Goll holds a degree in pharmacy from the Free University of Berlin and wrote her doctoral dissertation in natural sciences at Philipps University of Marburg. She was honored with a post-doctoral position supported by the Boehringer-Ingelheim Foundation for fundamental research in medicine. Alexandra is a qualified supervisory board member certified by Deutsche Börse.

She was a columnist for German VC Magazin and was elected one of Europe’s 40 most influential Private Equity and Venture Capital managers by industry voice Private Equity News in 2008.


Selected International Investments:


VC Financing, IPO, Follow on Financings


VC Financing, IPO, Member of the Board


VC Financing, Business Development, Reverse Takeover, US IPO, Member of the Board


VC /PE Financing, Trade Sale, Member of the Board


VC Financing Partner Strategy (Novartis), IPO, Member of the Board


PIPE Financing, Member of the Board


VC Financing, IPO, Member of the Board


VC Financing, strategic products and pipeline planning, shareholder restructuring, IPO, Member of the Board

Your Message

We will gladly answer your questions.

Legal Notice

Responsible for this website:

Alexandra Goll
Biopharma Advisory
Schreyeggstrasse 3
82229 Seefeld


Phone: +49 172 8320 597


Tax number:

Dispute resolution

The European Commission provides a platform for online dispute resolution (OS):
Please find our email above.